Sunday, February 10, 2019

expanded access program

Because each of the 11 study sites applied its own record of new drug research to the expanded access program, there was some variability in the eligibility criteria between centers. Specifically, some patients were taking more than four antiepileptic drugs (up to seven drugs in some patients) and some patients did not have seizures with a prominent CBD Gummies, sustained and accounting engine component.

Exclusion criteria for the entire study included previous or current treatment with cannabis-based therapy. The majority of the sites also excluded patients with hepatic, renal or hematologic baseline laboratory abnormalities or with onset of felbamate or vigabatrin within 6 months after the first clinical consultation.

No comments:

Post a Comment